This trial has been completed.

Condition constipation
Treatment bli400 laxative
Phase phase 2
Sponsor Braintree Laboratories
Start date December 2015
End date April 2016
Trial size 33 participants
Trial identifier NCT02665728, BLI400-201


The objective of this study is to evaluate the safety and efficacy of BLI400 laxative in constipated adolescent subjects.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
BLI400 Laxative
bli400 laxative

Primary Outcomes

Treatment response
time frame: 4 weeks

Eligibility Criteria

All participants from 12 years up to 17 years old.

Inclusion Criteria: - Male or female subjects at between 12-17 years of age - Weight more than 40 kg (88 lbs.). - Constipated, defined by the following criteria 1. Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months: 1. Straining during > 25% of defecations 2. Lumpy or hard stools in > 25% of defecations 3. Sensation of incomplete evacuation for > 25% of defecations 2. Loose stools are rarely present without the use of laxatives 3. There are insufficient criteria for irritable bowel syndrome - loose (mushy) or watery stool in the absence of laxative use for more than 25% of bowel movements Criteria A, B and C must be fulfilled for the last 12 weeks with symptom onset at least 6 months prior to diagnosis. - Otherwise in good health, as determined by physical exam and medical history - If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intrauterine device, double-barrier method, depot contraceptive, sterilized, or abstinence) - Negative urine pregnancy test at screening, if applicable - In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study Exclusion Criteria: - Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon - Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1 - Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1 - Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 3 - Subjects who are pregnant or lactating, or intend to become pregnant during the study - Subjects of childbearing potential who refuse a pregnancy test - Subjects who are allergic to the study medication - Subjects taking narcotic analgesics or other medications known to cause constipation - Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures - Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days - Subjects with an active history of drug or alcohol abuse - Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1 - Subjects who withdraw consent at any time prior to completion of Visit 1 procedures

Additional Information

Official title A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Braintree Laboratories.